[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Bakshi J, Panda NK, Ghoshal S, Nehru VI: Survival patterns in patients with carcinoma base of tongue treated with external beam irradiation and salvage surgery. Indian J Otolaryngol Head Neck Surg; 2010 Jun;62(2):142-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival patterns in patients with carcinoma base of tongue treated with external beam irradiation and salvage surgery.
  • OBJECTIVE: The current study was designed to assess the treatment results and survival in the patients with carcinoma of base of tongue that were treated with primary radiotherapy, radiotherapy with chemotherapy and salvage surgery when indicated.
  • DESIGN: A prospective study was carried out in 78 cases of carcinoma of the base of tongue between 1995 and 1999.
  • Radiotherapy in the dose of 60 Gy was given primarily to the patients with stage III tongue base cancer.
  • For the patients with advanced stage IV disease with poor general condition, palliative radiotherapy of 24 Gy with or without palliative chemotherapy was given.
  • CONCLUSIONS: External beam radiotherapy with salvage surgery results in satisfactory local and regional control in stage III and IV carcinoma base of tongue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1990 Oct;160(4):415-9 [2221246.001]
  • [Cites] J Surg Oncol. 1989 Jul;41(3):165-71 [2501592.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Apr;13(4):511-6 [3558042.001]
  • [Cites] Laryngoscope. 1983 Jan;93(1):20-5 [6823172.001]
  • [Cites] Laryngoscope. 1994 Dec;104(12):1446-52 [7990632.001]
  • [Cites] Head Neck. 1993 Jul-Aug;15(4):300-7 [8360051.001]
  • [Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]
  • [Cites] Laryngoscope. 2001 Aug;111(8):1362-5 [11568569.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Sep;137(3):422-7 [17765769.001]
  • (PMID = 23120701.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3450302
  • [Keywords] NOTNLM ; Base of tongue / Radiation therapy / Salvage surgery / Survival
  •  go-up   go-down


2. Puri T, Singh K, Sharma DN, Khurana N: Epithelial-myoepithelial carcinoma of the base of tongue: pathology and management. Indian J Cancer; 2004 Jul-Sep;41(3):138-40
Genetic Alliance. consumer health - Myoepithelial carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-myoepithelial carcinoma of the base of tongue: pathology and management.
  • Epithelial-myoepithelial carcinoma is a rare tumor which makes up about 0.2% of epithelial neoplasms of the salivary glands; parotid gland being the most common primary site of origin.
  • The tumor may also very rarely originate in minor salivary glands of the base of the tongue.
  • Due to rarity of its occurrence, histogenesis and clear cut therapeutic guidelines are not defined.
  • The present report describes the case of a 48 year old male who was diagnosed to have a tubular variant of epithelial-myoepithelial carcinoma of the base of tongue, Stage T3 N0 M0 (Stage group III).
  • The patient was treated with neoadjuvant chemotherapy followed by radical radiotherapy (Rt) and is alive with no evidence of disease 14 months following end of treatment.
  • [MeSH-major] Myoepithelioma. Neoplasms, Glandular and Epithelial. Tongue Neoplasms
  • [MeSH-minor] Humans. Male. Middle Aged. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Epithelial-Myoepithelial Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15472415.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


3. Diaz R, Blakey MD, Murphy PB, Cryar AK, Cmelak AJ: Thyroid storm after intensity-modulated radiation therapy: a case report and discussion. Oncologist; 2009 Mar;14(3):233-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid storm after intensity-modulated radiation therapy: a case report and discussion.
  • A 43-year-old man with locally advanced squamous cell carcinoma of the base of tongue was treated with induction chemotherapy followed by intensity-modulated radiation therapy (IMRT).
  • Within 20 days post-treatment, the patient developed clinical symptoms highly suggestive of hyperthyroidism.
  • Two and one half months after completion of therapy, the patient developed severe thyrotoxicosis, which, in retrospect, appears to have met the criteria for thyroid storm.
  • This case history illustrates a previously unreported, life-threatening complication of external-beam radiation that should be considered in patients receiving IMRT therapy involving the thyroid.
  • Diagnosis of the patient's hyperthyroidism and probable thyroid storm was difficult to recognize because of the significant overlap between the signs and symptoms of severe thyrotoxicosis and the expected toxicities of his cancer therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Radiation Injuries / etiology. Thyroid Crisis / etiology. Tongue Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Radiotherapy, Intensity-Modulated / adverse effects. Thyroid Hormones / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19286762.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thyroid Hormones
  •  go-up   go-down


Advertisement
4. Kumar M, Bahl A, Sharma DN, Sharma R, Gupta R, Ahmed S, Julka PK, Rath GK: Cylindric cell carcinoma of the base of the tongue: a rare variant of squamous cell carcinoma. J Cancer Res Ther; 2009 Apr-Jun;5(2):124-6
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cylindric cell carcinoma of the base of the tongue: a rare variant of squamous cell carcinoma.
  • They have been known by myriads of nomenclature like cylindric carcinomas, nonkeratinizing sinonasal carcinoma, papillary carcinoma, cylindrical or columnar cell carcinoma, intermediate cell carcinoma, Schneiderian carcinoma, and Ringertz carcinoma.
  • They are considered a variant of nonkeratinizing squamous cell carcinoma.
  • Only passing references have been made for its presentation in oropharynx including tonsils and the base of the tongue.
  • We report here a rare case of transitional cell carcinoma presenting in the base of the tongue.
  • There are no separate treatment recommendations in the literature, and the management is on the lines of treatment of squamous cell carcinoma.
  • We report here a case of cylindric cell carcinoma presenting in the base of the tongue.
  • The patient received palliative radiotherapy of 20 Gy in five fractions followed by chemotherapy with injection paclitaxel and carboplatin.
  • A partial response to treatment was achieved at the time of writing this report.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542670.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


5. Jegannathen A, Swindell R, Yap B, Lee L, Sykes A, Mais K, Sanghera P, Hartley A, Glaholm J, Slevin N: Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Clin Oncol (R Coll Radiol); 2010 Apr;22(3):185-91
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer?
  • AIM: To evaluate the tolerability of synchronous chemotherapy and accelerated hypofractionated radiotherapy in patients with locally advanced squamous cell carcinoma of the base of the tongue.
  • MATERIALS AND METHODS: Between 1999 and 2004, 43 patients with stage II-IV squamous cell carcinoma of the base of the tongue were treated with a combined modality of radiotherapy (prescribed 55 Gy in 20 fractions), synchronous chemotherapy and in some cases surgical neck dissection.
  • All patients completed radiotherapy and 30% received neoadjuvant chemotherapy.
  • The median time for the completion of treatment was 27 days (range 25-36).
  • Overall, only 42% completed the prescribed synchronous chemotherapy.
  • However, compliance increased to 60% in patients who did not receive neoadjuvant chemotherapy.
  • Grade 3 mucositis developed in 90% of patients.
  • Prolonged grade 3 mucositis (>4 weeks) was seen in 24/43 (56%) and none developed grade 4 mucositis.
  • CONCLUSION: The addition of synchronous chemotherapy to accelerated hypofractionated radiotherapy consistently led to grade 3 mucositis.
  • Higher mucosal toxicity and lower synchronous chemotherapy compliance compared with other series may suggest that this approach is at the limit of patient tolerability.
  • However, the tumour site investigated and the choice of synchronous chemotherapy agent may also be important.
  • Longer fractionation will probably increase compliance with chemotherapy, particularly when induction is used before synchronous treatment.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / therapy. Radiotherapy / methods. Tongue Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Tongue cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20116980.001).
  • [ISSN] 1433-2981
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Karakoyun-Celik O, Norris CM Jr, Tishler R, Mahadevan A, Clark JR, Goldberg S, Devlin P, Busse PM: Definitive radiotherapy with interstitial implant boost for squamous cell carcinoma of the tongue base. Head Neck; 2005 May;27(5):353-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive radiotherapy with interstitial implant boost for squamous cell carcinoma of the tongue base.
  • BACKGROUND: The purpose of this study was to examine the long-term outcome of a cohort of patients with unresected base of tongue carcinoma who received interstitial brachytherapy after comprehensive external beam radiation therapy.
  • METHODS: Between 1983 and 2000, 122 patients with primary or recurrent squamous cell carcinoma of the oropharynx or oral cavity received interstitial brachytherapy as part of their overall management.
  • Forty patients had primary, unresected carcinoma of the base of tongue and are the subjects of this analysis.
  • Twenty-four (60%) received two to three cycles of neoadjuvant chemotherapy.
  • The oropharynx, bilateral neck, and supraclavicular fossae were comprehensively irradiated, and the tongue base received a median external beam dose of 61.2 Gy (50-72 Gy).
  • The primary site was then boosted with an interstitial 192Iridium implant by use of a gold-button single-strand technique and three-dimensional treatment planning.
  • The dose rate was prescribed at 0.4 to 0.5 Gy/hr.
  • The median implant dose was 17.4 Gy (9.6-24 Gy) and adjusted to reach a total dose to the primary tumor of 80 Gy.
  • N2 to 3 disease was managed by a planned neck dissection performed at the time of the implant.
  • The overall survival and primary site control were independent of T classification, N status, or overall stage.
  • Systemic therapy was associated with an improvement in overall survival (p = .04) and a trend toward increased primary site control with greater clinical response.
  • CONCLUSIONS: In an era of greatly improved dose distributions made possible by three-dimensional treatment planning and intensity-modulated radiation therapy, brachytherapy allows a highly conformal dose to be delivered in sites such as the oropharynx.
  • If done properly, the procedure is safe and delivers a dose that is higher than what can be achieved by external beam radiation alone with the expected biologic advantages.
  • The long-term data presented here support an approach of treating advanced tongue base lesions that includes interstitial brachytherapy as part of the overall management plan.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Squamous Cell / therapy. Tongue Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Dose-Response Relationship, Radiation. Female. Follow-Up Studies. Humans. Iridium Radioisotopes / therapeutic use. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy, Computer-Assisted. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley Periodicals, Inc.
  • (PMID = 15726587.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iridium Radioisotopes
  •  go-up   go-down


7. Steiner W, Fierek O, Ambrosch P, Hommerich CP, Kron M: Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg; 2003 Jan;129(1):36-43
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue.
  • OBJECTIVE: To determine the role of transoral laser microsurgery for base of tongue squamous cell carcinoma.
  • DESIGN: Retrospective unicenter study of the oncologic and functional results of laser microsurgery of tongue base carcinoma performed between 1986 and 1997.
  • PATIENTS: We reviewed 48 previously untreated patients with base of tongue squamous cell carcinoma, who were treated with transoral laser microsurgery.
  • Selective neck dissection was performed in 43 patients; 23 patients underwent postoperative radiotherapy with or without simultaneous chemotherapy.
  • Twenty-one patients survived at least 5 years after treatment.
  • CONCLUSIONS: Our concept of organ and function preserving laser microsurgery for selected patients with base of tongue cancer seems to be justified considering the achieved oncological and functional results.
  • Final proof of the effectiveness of the new therapeutic concept presented herein requires well-designed prospective studies.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Laser Therapy. Tongue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Microsurgery. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12525192.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Lawson JD, Otto K, Chen A, Shin DM, Davis L, Johnstone PA: Concurrent platinum-based chemotherapy and simultaneous modulated accelerated radiation therapy for locally advanced squamous cell carcinoma of the tongue base. Head Neck; 2008 Mar;30(3):327-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent platinum-based chemotherapy and simultaneous modulated accelerated radiation therapy for locally advanced squamous cell carcinoma of the tongue base.
  • BACKGROUND: Randomized data support use of chemotherapy concurrently with radiation in treatment of advanced squamous cell carcinoma (SCC) of the oropharynx.
  • Intensity modulated radiation therapy (IMRT) is increasingly being used to deliver such radiotherapy; no published reports specifically describe results of chemotherapy with IMRT for SCC of the base of tongue (BOT).
  • We present outcomes data using simultaneous modulated accelerated radiation therapy (SMART) combined with platinum-based chemotherapy in treatment of locally advanced SCC of the BOT METHODS: The records of the Otolaryngology/Head and Neck Surgery Department of Emory University were screened for patients undergoing definitive chemoradiotherapy for SCC of the BOT.
  • All patients were treated definitively with platinum-based chemotherapy and once-daily RT.
  • Median dose and dose per fraction to sites of gross primary or nodal disease, clinically involved neck, and clinically uninvolved neck were 70.29 Gy (2.13 Gy/fx), 63.03 Gy (1.91 Gy/fx), and 57.75 Gy (1.75 Gy/fx), respectively.
  • RESULTS: Between January 2003 and August 2005, 34 patients underwent definitive therapy for SCC of the BOT using SMART and chemotherapy.
  • CONCLUSION: With moderate follow-up, chemotherapy and SMART contributes to excellent results, with 24-month actuarial overall survival and local control of 90% and 92%, respectively.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Tongue Neoplasms / mortality. Tongue Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Drug Administration Schedule. Female. Follow-Up Studies. Gastrostomy. Humans. Male. Middle Aged. Neck Dissection. Paclitaxel / therapeutic use. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley Periodicals, Inc. Head Neck 2008
  • (PMID = 17657789.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Grant] United States / NIMHD NIH HHS / MD / 5P60 MD000525; United States / NCI NIH HHS / CA / R01 CA112643; United States / NCI NIH HHS / CA / U01 CA101244
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Pradier O, Christiansen H, Ambrosch P, Kron M, Schmidberger H, Hess CF: A long-term follow-up study after split-course irradiation with concurrent chemotherapy (carboplatin) for locally advanced head and neck cancer and a review of the literature. ORL J Otorhinolaryngol Relat Spec; 2004;66(6):325-31
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term follow-up study after split-course irradiation with concurrent chemotherapy (carboplatin) for locally advanced head and neck cancer and a review of the literature.
  • BACKGROUND: Radiotherapy is often the primary treatment for advanced head and neck cancer, but the rates of locoregional recurrence are high and survival is poor.
  • The purpose of this study was to evaluate the efficacy and toxicity of split-course radiotherapy combined with concurrent carboplatin chemotherapy after long-term follow-up.
  • Tumour localization in the oropharynx was: tonsil (n = 33), base of tongue (n = 28), soft palate (n = 2) and posterior pharyngeal wall (n = 3).
  • A total radiation dose of 5,670 cGy was applied in 6 weeks as a split-course regimen (2 x 2.1 Gy/day, 4 times a week, weeks 1 and 2 and weeks 5 and 6).
  • Concomitant carboplatin chemotherapy was given each radiotherapy day before irradiation (50 mg/m(2)).
  • Therapy was tolerated moderately (19% grade 3 skin reaction, 26% grade 3 mucositis, 23% grade 3 xerostomia, 20% grade 3 leucopenia, 8% grade 3 thrombopenia and 25% grade 3 anaemia).
  • CONCLUSION: Split-course radiotherapy and concomitant carboplatin chemotherapy can be carried out in inoperable head and neck cancer without severe toxicity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / methods. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel.
  • (PMID = 15668532.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  • [Number-of-references] 46
  •  go-up   go-down


10. Wojdas A, Jurkiewicz D, Kenig D, Rapiejko P: [The case of carcinoma adenoides cysticum of the tongue, the trachea and the thyroid gland]. Otolaryngol Pol; 2004;58(6):1151-5
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The case of carcinoma adenoides cysticum of the tongue, the trachea and the thyroid gland].
  • We present a case of a 65-year-old female patient who was for the first time admitted to the clinic in 1997 due to a tuber of the tongue root.
  • The patient was re-admitted to the Clinic in 2001 due to a tuber of the tongue and of the oral cavity bottom.
  • The tuber was removed entirely through a central incision, and an apart hypertrophic change has been found on the posterior pharynx wall and in the scar after the tracheostomy carried out during the previous surgery.
  • In all cases carcinoma adenoides cysticum has been found, as well as metastasis into the thyroid gland and the lungs.
  • The patient was qualified for chemotherapy in the Institute of Oncology, which she has been going through periodically every two weeks until now.
  • Carcinoma adenoides cysticum was found.
  • In February 2003 the patient was re-admitted to the Clinic due to dyspnoea caused by a significant contraction of the trachea which occurred as a result of a focus of carcinoma adenoides cysticum and significantly enlarged lymph glands near the trachea.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Thyroid Neoplasms / pathology. Tongue Neoplasms / pathology. Tracheal Neoplasms / pathology
  • [MeSH-minor] Bronchoscopy / methods. Female. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732839.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


11. Nakamura T, Kodaira T, Tachibana H, Tomita N, Yokouchi J, Fuwa N: Clinical outcome of oropharyngeal carcinoma treated with platinum-based chemoradiotherapy. Oral Oncol; 2009 Sep;45(9):830-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of oropharyngeal carcinoma treated with platinum-based chemoradiotherapy.
  • To determine the efficacy, feasibility, and toxicity of treated with platinum-based chemoradiotherapy for oropharyngeal carcinoma.
  • A retrospective survey of 91 patients who underwent platinum-based chemotherapy and radiotherapy for oropharyngeal cancer at Aichi Cancer Center Hospital between 1971 and 2003.
  • Nine patients who had a tumor in the base of the tongue were also treated with arterial infusion chemotherapy.
  • At a median follow-up of 63months (range, 2-190 months), 26 (29%) patients developed recurrence.
  • Five patients (5%) developed distant metastases.
  • The 5-year local control rate for each subsite was: anterior wall, 90%; lateral wall, 80%; posterior wall, 67%; and superior wall, 64%.
  • Two patients developed grade 3 (mandibular bone necrosis) or 4 (laryngeal edema) late toxicities.
  • In this study, platinum-based chemoradiotherapy provided good local control for oropharyngeal carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy / methods. Disease-Free Survival. Feasibility Studies. Female. Fluorouracil / administration & dosage. Humans. Japan. Male. Middle Aged. Neoplasm Recurrence, Local. Organoplatinum Compounds / administration & dosage. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19457713.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Gourin CG, Johnson JT: Surgical treatment of squamous cell carcinoma of the base of tongue. Head Neck; 2001 Aug;23(8):653-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of squamous cell carcinoma of the base of tongue.
  • INTRODUCTION: Squamous cell carcinoma (SSC) of the tongue base has historically been shown to be associated with a poor prognosis.
  • We reviewed our experience with primary surgery followed by postoperative radiation therapy (XRT) to determine the impact of our treatment protocols on outcome.
  • METHODS: We retrospectively reviewed the records of all patients presenting to the University of Pittsburgh with previously untreated SSC of the tongue base between 1980-1997.
  • Adjuvant chemotherapy was offered if histologic signs of aggressive behavior were identified (multiple nodes or extracapsular spread).
  • Local recurrence occurred in 5 patients, regional recurrence occurred in 12 patients, and distant metastases developed in 22 patients.
  • CONCLUSIONS: Surgical treatment of SCC of the tongue base is highly effective in achieving local disease control and disease-free survival for early lesions.
  • Because both functional outcome and survival are poor after surgical treatment of advanced lesions, we now offer brachytherapy with XRT or participation in a combined chemoradiation protocol rather than primary surgical therapy to patients with advanced disease.
  • Prospective studies are needed to compare the effect of these organ-preserving therapies with traditional combined surgery and XRT to determine the effect on functional outcome and quality of life.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Tongue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Glossectomy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Postoperative Complications. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11443748.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Kljajić V, Jović R, Canji K, Nikolin B, Gavrilović M: [Surgical techniques and outcomes in the treatment of malignant tongue base tumors]. Med Pregl; 2007 Jan-Feb;60(1-2):49-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical techniques and outcomes in the treatment of malignant tongue base tumors].
  • INTRODUCTION: Prognosis of patients with malignant tongue base tumors is poor.
  • Survival is low, in spite of different treatment modalities.
  • Most patients seek treatment too late, when their disease has already progressed to stage III or IV.
  • The aim of this investigation was to compare different treatment modalities in patients with malignant tongue base tumors.
  • Planocellular cancer was diagnosed in 79/82 patients, and the remaining (3182) had transitional cell carcinoma.
  • Surgical treatment alone was performed in 17 patients, seven were treated with radiation only, and nine only with chemotherapy.
  • Combined surgical and radiation therapy was performed in 28 patients, and 5 were treated with all three.
  • Ten patients were not treated with any therapy.
  • Tongue base resection only was performed in 12 patients, tongue base resection with epiglottectomy in 20, tongue base resection with supraglottic laryngectomy in 13 and tongue base resection with total laryngectomy in 5 patients.
  • Five-year survival after combined surgical and radiation therapy was 35% CONCLUSION: Development of tongue base carcinoma is strongly associated with alcohol and tobacco consumption.
  • Survival is low, despite various treatment modalities.
  • However, combined therapy is the therapy of choice in cases with tongue base carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / surgery. Tongue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17853711.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


14. Culp LR, Pou AM, Jones DV, Bayouth J, Sanguineti G: A case of radiation recall mucositis associated with docetaxel. Head Neck; 2004 Feb;26(2):197-200
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We report a case of a 45-year-old man diagnosed with squamous cell carcinoma of the base of tongue.
  • He was treated with surgery followed by chemotherapy and radiation therapy.
  • Several months after completing treatment, he had a recurrence develop outside of the previously irradiated field.
  • He was offered radiation therapy concurrent with docetaxel as salvage therapy.
  • RESULTS: During salvage therapy, acute recall mucositis developed corresponding to his previously irradiated fields.
  • His chemotherapy with docetaxel was withheld, and his symptoms rapidly improved.
  • Given the potential severity of the reaction and increasing use of docetaxel as second-line treatment of recurrent head and neck cancers, it is important to be aware of this phenomenon.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Carcinoma, Squamous Cell / surgery. Mucous Membrane / drug effects. Neoplasm Recurrence, Local / radiotherapy. Radiation-Sensitizing Agents / adverse effects. Radiodermatitis / etiology. Taxoids / adverse effects. Tongue Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Inflammation / etiology. Male. Middle Aged. Radiotherapy, Adjuvant

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley Periodicals, Inc. Head Neck 26: 197-200, 2004
  • (PMID = 14762890.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Radiation-Sensitizing Agents; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


15. Shin HA, Lim YC, Jeong HM, Choi EC: Role of primary surgery for early-stage (T1-2N0) squamous cell carcinoma of the oropharynx. Oral Oncol; 2009 Dec;45(12):1063-6
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of primary surgery for early-stage (T1-2N0) squamous cell carcinoma of the oropharynx.
  • To evaluate treatment outcomes and the role of primary definitive surgery for T(1-2), clinically N(0) oropharyngeal squamous cell carcinoma (OPSCC) patients, we performed a retrospective analysis of 46 consecutive cases treated primarily by surgery and/or postoperative radiotherapy at Yonsei University between May 1992 and December 2006.
  • The most common location was the tonsil (54%), followed by the soft palate (19%), the base of the tongue (BOT) (15%) and the posterior wall (12%).
  • Almost 30% of all patients may be candidates for adjuvant chemotherapy through histopathologic analysis according to the National Comprehensive Cancer Network (2007) guidelines.
  • The results of the present study demonstrate excellent oncologic outcomes with primary surgery for the treatment of early-stage OPSCC and suggest that surgery offers the best opportunity to identify patients in whom adjuvant radio- or chemotherapy may be most appropriately applied.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Oropharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Republic of Korea. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19717331.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Walvekar RR, Li RJ, Gooding WE, Gibson MK, Heron D, Johnson JT, Ferris RL: Role of surgery in limited (T1-2, N0-1) cancers of the oropharynx. Laryngoscope; 2008 Dec;118(12):2129-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Forty-nine limited oropharyngeal squamous cell cancers of the tonsil, tongue base, or posterior pharyngeal wall-treated surgically were identified.
  • Among 35 disease-free patients, 28% (4/20) of stage I/II patients received postoperative radiation and chemotherapy was avoided in 80% (12/15) of stage III patients.
  • CONCLUSIONS: Surgical staging identifies patients in whom intensification of treatment with chemotherapy can be most appropriately applied, and enables de-intensification of therapy in pathology confirmed stage I/II disease.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Neck Dissection. Oropharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948826.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Kotz T, Costello R, Li Y, Posner MR: Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck. Head Neck; 2004 Apr;26(4):365-72
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck.
  • METHODS: Twelve patients with stage III or IV squamous cell carcinoma of the head and neck were enrolled.
  • Postchemoradiation videofluorographic swallowing studies were performed from 1 to 14 weeks after the completion of treatment (mean, 8 weeks).
  • RESULTS: Changes in swallowing physiology after treatment included decreased base of tongue to posterior pharyngeal wall contact (p =.0010) and reduced pharyngeal contraction (p =.0313), resulting in impaired bolus transport through the pharynx.
  • CONCLUSIONS: Organ preservation treatment impairs movement of structures essential for normal swallowing.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Deglutition Disorders / etiology. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Fluoroscopy. Humans. Inhalation / physiology. Larynx / physiopathology. Male. Middle Aged. Pharynx / physiopathology. Radiotherapy / adverse effects. Sampling Studies. Video Recording


18. Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Mancuso AA: Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck; 2003 Jul;25(7):535-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck.
  • PURPOSE: To analyze parameters that may influence the likelihood of local control after definitive radiotherapy for head and neck cancer.
  • METHODS: Between April 1980 and January 2000, 404 patients were treated with definitive RT alone (358 patients) or combined with adjuvant chemotherapy (46 patients) at our institution and were followed up for 0.25 to 20.25 years (median, 3.5 years.
  • Parameters evaluated in multivariate analyses of these end points included primary site, T stage, primary tumor volume, N stage, histologic differentiation, fractionation schedule, adjuvant chemotherapy, and gender.
  • Multivariate analyses stratified by primary site revealed that tumor volume significantly influenced local control for patients with cancers of the supraglottis (p =.0220) and glottis (p =.0042) but not for those with lesions of the tonsillar fossa/posterior tonsillar pillar (p =.0892), base of tongue (p =.9493), anterior tonsillar pillar/soft palate (p =.5909), and hypopharynx (p =.2282).
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Predictive Value of Tests. Radiotherapy / adverse effects. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley Periodicals, Inc. Head Neck 25: 535-542, 2003
  • (PMID = 12808656.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Namazie A, Alavi S, Abemayor E, Calcaterra TC, Blackwell KE: Adenoid cystic carcinoma of the base of the tongue. Ann Otol Rhinol Laryngol; 2001 Mar;110(3):248-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the base of the tongue.
  • A retrospective review of 14 patients with adenoid cystic carcinoma of the tongue treated between 1955 and 1997 was performed.
  • Treatment consisted of surgery (n = 2), radiotherapy (n = 2), chemotherapy (n = 1), or combination therapy (n = 9).
  • Surgical extirpation combined with postoperative radiotherapy is advocated for the treatment of adenoid cystic carcinoma of the tongue.
  • [MeSH-major] Carcinoma, Adenoid Cystic / therapy. Tongue Neoplasms / therapy

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11269769.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement